Table 1. Stakeholder participation in development of the consensus conceptual model

Stakeholder group	Investment
People affected by PD • Patients • Families (Spouse/partners, children, close friends)	• ***Taskforce member***: PwP representative at monthly taskforce meetings to consult on approach, progress, and co-author final product • ***Advisory panel:*** Ethnically and gender diverse 9-member patient advisory panel convened to (A) review and advise on approach developed by taskforce; (B) provide iterative real-time feedback on model structure, terminology, presentation, and potential uses; (C) review and provide feedback on final manuscript and results; (D) co-authors on final manuscript. Panel characteristics:
Clinicians (Neurology, PCP, Nursing, Speech/PT)	**Multi-stakeholder taskforce convened monthly to:** • Co-develop approach • Monitor progress • Advise on data extraction and meta-synthesis • Critique and iteratively revise model and outputs • Co-author presentations, publications **Public Review Period** • One-month public review period to provide feedback on final report.
Researchers • Model developers; PD staging experts, Topical experts	
PD Advocacy Groups • Michael J Fox Foundation • Parkinson's UK	
Industry • Roche, AbbVie, GSK, Roche, Denali, UCB	
Representatives of professional agencies • Critical Path for Parkinson’s • Movement Disorders Society	
Regulatory • FDA • National Council on Aging • CMS (Center for Medicare Services)	• Review and provide feedback on draft methods and results. • Review and provide feedback on final report